Evidence map›Paper›PMID 42097191›Full record

ReviewArchives of biochemistry and biophysics2026

Interplay between NRF2 post-translational modifications and protein-protein interactions: Perspectives from emerging structural and functional evidence.

Adem Ozleyen, Seda Savranoglu Kulabas, Miroslav Novak, Milena Cichoń, Cristina Matas De Las Heras, Tadashi Honda, Richard G Doveston, Albena T Dinkova-Kostova, Anna Grochot-Przeczek, Tugba Boyunegmez Tumer

Abstract readReview
In one paragraph

Review in Archives of biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adem OzleyenHealth Institutes of Turkiye, Turkiye Biotechnology Institute, Ankara, 06270, Turkiye.
Seda Savranoglu KulabasDepartment of Immunology, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale, Turkiye.
Miroslav NovakDivision of Cancer Research, School of Medicine, University of Dundee, Scotland, United Kingdom.
Milena CichońDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland; Doctoral School of Exact and Natural Sciences, Jagiellonian University, Kraków, Poland.
Cristina Matas De Las HerasLeicester Institute for Structural and Chemical Biology, University of Leicester, Leicester, LE1 7RH, United Kingdom; School of Chemistry, University of Leicester, Leicester, LE1 7RH, United Kingdom.
Tadashi HondaDepartment of Chemistry and Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, NY, USA.
Richard G DovestonLeicester Institute for Structural and Chemical Biology, University of Leicester, Leicester, LE1 7RH, United Kingdom; School of Chemistry, University of Leicester, Leicester, LE1 7RH, United Kingdom.
Albena T Dinkova-KostovaDivision of Cancer Research, School of Medicine, University of Dundee, Scotland, United Kingdom; Department of Physiology, Pharmacology and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Anna Grochot-PrzeczekDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland. Electronic address: anna.grochot-przeczek@uj.edu.pl.
Tugba Boyunegmez TumerDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland; Department of Molecular Biology and Genetics, Faculty of Arts and Science, Canakkale Onsekiz Mart University, Canakkale, 17020, Turkiye. Electronic address: tumertb@comu.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear factor erythroid 2-related factor 2 (NRF2), a redox-sensitive transcription factor, is a master regulator of cellular adaptation to diverse types of stressors. Under basal conditions, the regulation of NRF2 is governed by Kelch-like ECH-associated protein 1 (KEAP1), an adaptor subunit of the CUL3-based E3 ubiquitin ligase, which promotes the ubiquitination and subsequent degradation of NRF2. However, when electrophilic or oxidative stressors alter the conformation of the KEAP1-NRF2 complex, KEAP1 loses its regulatory control over newly synthesized NRF2, leading to its accumulation and nuclear translocation, where it exerts transcriptional activity. NRF2 stability and activity are also shaped by a broader spectrum of protein-protein interactions (PPIs), including recently emerging regulators such as peptidyl prolyl isomerase (PIN1). Significantly, many of these dynamic PPI networks are regulated by post-translational modifications (PTMs), which, in turn, can be governed by these PPIs. While major PTMs such as phosphorylation and ubiquitination constitute the central regulatory processes, atypical or less-characterized modifications, including SUMOylation and O-GlcNAcylation, are gaining increasing attention for their tissue and condition-specific roles. This review compiles the latest structural and functional evidence on well-known as well as understudied PTMs and PPIs of NRF2, emphasizing the dynamic interplay between these regulatory mechanisms in shaping NRF2 signaling under physiological and stress conditions.

Indexed as

NF-E2-Related Factor 2Protein Processing, Post-TranslationalAnimalsHumansKelch-Like ECH-Associated Protein 1Protein BindingUbiquitinationKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2KEAP1NRF2PPIsPTM-CodeRegulatory mechanisms

Identifiers

PMID42097191
PMCPMC13271694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.